Completed
An Open-Label, Long-Term, Multi-Center, Intrathecal Ziconotide (PRIALT) Effectiveness and Safety Trial (ZEST) in Patients With Chronic Severe Pain
What is being tested
Data Collection
Who is being recruted
Neurologic Manifestations+1
+ Pain
+ Signs and Symptoms
Over 18 Years
+13 Eligibility Criteria
How is the trial designed
Treatment Study
Phase 3
Interventional
Study Start: February 2004
Summary
Principal SponsorElan Pharmaceuticals
Last updated: January 27, 2026
Sourced from a government-validated database.Claim as a partner
Study start date: February 1, 2004
Actual date on which the first participant was enrolled.The purpose of this open-label study is to give chronic severe pain patients with existing intrathecal pump systems access to ziconotide.
Official TitleAn Open-Label, Long-Term, Multi-Center, Intrathecal Ziconotide (PRIALT) Effectiveness and Safety Trial (ZEST) in Patients With Chronic Severe Pain
Principal SponsorElan Pharmaceuticals
Last updated: January 27, 2026
Sourced from a government-validated database.Claim as a partner
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.Design Details
300 patients to be enrolled
Total number of participants that the clinical trial aims to recruit.Treatment Study
These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Conditions
Criteria
Any sex
Biological sex of participants that are eligible to enroll.Over 18 Years
Range of ages for which participants are eligible to join.Healthy volunteers not allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
Neurologic ManifestationsPainSigns and SymptomsPathological Conditions, Signs and Symptoms
Criteria
8 inclusion criteria required to participate
Each patient must have chronic severe pain of malignant or nonmalignant etiology with inadequate pain relief from or intolerance to conventional therapy.
Each patient must have a predicted life expectancy of greater than or equal to 6 weeks relative to baseline.
Each patient must be able to respond to the Visual Analog Scale of Pain Intensity (VASPI).
Each patient must have an implanted programmable SynchroMed infusion device or a CADD-Micro external programmable infusion device and spinal catheter (hereafter "IT pump and spinal catheter") prior to enrollment into this trial. (If a patient has an external pump, the Investigator must ensure that the patient is at a low risk for infection and that the patient is capable of maintaining good personal hygiene. The Investigator must have demonstrated the ability to successfully manage patients with external pumps prior to enrolling a patient in this trial.)
Show More Criteria
5 exclusion criteria prevent from participating
Presence of pregnancy or lactation.
Participation in another investigational drug or device trial within the preceding 30 days.
Presence of known hypersensitivity to PRIALT or any of its components.
Presence of any contraindication to continued IT therapy (for example, infection at the pump or catheter externalization site, uncontrolled bleeding diathesis, spinal canal obstruction that impairs cerebrospinal fluid [CSF] circulation, or patient and caregiver inability to manage and protect the IT pump and spinal catheter system and return for clinic follow up visits).
Show More Criteria
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has 65 locations
Suspended
Suspended
Center for Pain Management
Huntsville, United StatesSuspended
Otto Uhrik, MD
Sun City West, United StatesSuspended
Outcomes Research International
Tucson, United StatesCompleted65 Study Centers